IMAF: First Money In Part 2: Entrepreneurs and Investments Entrepreneurs interested in the Inception Micro Angel Fund (IMAF) for start-up money should not be influenced by the geographical names, Triad, East, Western, Charlotte, Triangle and, soon, Coastal. “Geography doesn’t play the role it used to,” Tim Janke, IMAF executive director, said. “The way the IMAF family of funds work, we know the process and the... 

IMAF: First Money In Part 1: The Model and Membership Providing seed-stage funding, the first money into a start-up company, is probably the riskiest type of investing. Tim Janke, executive director of the Inception Micro Angel Fund (IMAF), emphasizes that the first round of independent financing is not only risky but absolutely critical. For emerging companies, the first gap in funding hits at $50,000 to $100,000.... 

Novozymes: From a Petro to a Bio Society According to the Biotechnology Industry Organization (BIO), bio-based products have the potential to replace 10 percent of US oil imports, significantly reduce CO2 emissions, create new revenue streams for US farmers and provide clean tech jobs in rural areas. A study released at the BIO World Congress held in Washington DC in June by the World Economic Forum (WEF) defines how... 

For Durham-based Tranzyme Pharma, the past year has been successful. Highlights include entering into a broad drug discovery partnership with Bristol-Myers Squibb and, most recently, a licensing agreement with Norgine B.V., a European specialty pharmaceutical company, for the exclusive rights to develop and commercialize Tranzyme’s novel ghrelin agonist, ulimorelin (TZP-101) in Europe, Australia, New Zealand, the Middle...